XML 96 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment and Geographic Information (Tables)
12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Schedule of Revenue by Geographic Area

Geographic revenues, which are based on the bill-to region, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Europe

 

$

132,400

 

 

$

112,916

 

 

$

110,861

 

Japan (related party)

 

 

122,475

 

 

 

100,002

 

 

 

20,111

 

All other

 

 

1,702

 

 

 

40

 

 

 

24

 

Total revenue

 

$

256,577

 

 

$

212,958

 

 

$

130,996

 

Schedule of Long Lived Assets by Geographic Area

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

United States

 

$

27,325

 

 

$

103,539

 

China

 

 

15,418

 

 

 

23,659

 

Total property and equipment

 

$

42,743

 

 

$

127,198

 

Summary of Finance and Operating Lease Right of Use Assets by Geographical Location

Finance lease right-of-use assets and operating lease right-of-use assets, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

United States

 

$

39,237

 

 

$

 

China

 

 

365

 

 

 

 

Total finance lease right-of-use assets

 

$

39,602

 

 

$

 

 

 

 

 

 

 

 

 

 

United States

 

$

75

 

 

$

 

China

 

 

1,856

 

 

 

 

Total operating lease right-of-use assets

 

$

1,931

 

 

$

 

Schedule of Customer Concentration by Collaboration Partners

Substantially all of the Company’s revenues to date have been generated from the following collaboration partners that respectively accounted for 10% or more of the Company’s total revenue and accounts receivable:

 

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

Years Ended December 31,

 

 

December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

 

2019

 

 

2018

 

Astellas—Related party

 

 

48

%

 

 

47

%

 

 

15

%

 

 

17

%

 

 

74

%

AstraZeneca

 

 

52

%

 

 

53

%

 

 

85

%

 

 

81

%

 

 

26

%